The present invention relates to novel pyridine nucleoside compounds, Neopetroside A (NPS A) and Neopetroside B (NPS B) obtained by fractionating an extract of Neopetrosia sp. which is a marine sponge, with ethanol, into n-butanol (n-BuOH). When the NPS A was treated with myocardial cells, it activates oxidative phosphorylation, basal and mitochondrial respiration induced by ATP and ATP synthesis, and stimulates the glycolysis activity and when the NPS A was treated with an ischemic reperfusion injury model, the left ventricular pressure injured by ischemic reperfusion was recovered and the size of myocardial injury site was significantly reduced and as a result, can be provided as the pharmaceutical composition for preventing or treating ischemic heart disease or the health functional food for preventing or improving the same.

The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from Carteriospongia sp. sponge: ##STR00001##
where R.sub.1 is CH.sub.3 or C.sub.2H.sub.5. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.

The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from Carteriospongia sp. sponge: ##STR00001##
where R.sub.1 is CH.sub.3 or C.sub.2H.sub.5. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.

Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.

Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.

The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from Carteriospongia sp. sponge:

##STR00001##

where R.sub.1 is CH.sub.3 or C.sub.2H.sub.5. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.

The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from Carteriospongia sp. sponge:

##STR00001##

where R.sub.1 is CH.sub.3 or C.sub.2H.sub.5. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.

The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.

The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.

The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.